{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-0", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 0, "text": "Trichomoniasis\nSkip to main content\nUNICEF/Schermbrucker\nA couple attends HIV testing and counseling, Malawi.\n©\nCredits\nTrichomoniasis\n21 November 2025\nKey facts\nTrichomoniasis is a common sexually transmitted infection (STI) among women of reproductive age, caused by the protozoan\nTrichomonas vaginalis\n.\nIt is treatable and curable.\nIn 2020 there were approximately 156 million new cases of\nT. vaginalis\ninfection among people aged 15–49 years old.\nIn females, trichomoniasis is a common cause of vaginal discharge and is associated with poor birth outcomes and increased risk of pelvic inflammatory disease.\nInfection with\nT. vaginalis\nis also associated with increased risk of HIV acquisition.\nOverview\nTrichomonas vaginalis\nis a preventable and curable sexually transmitted protozoan that infects the urogenital tract.\nMore than 50% of women with\nTrichomonas vaginalis\ninfection have vaginal discharge and about 10% of men have urethritis or urethral discharge.\nCorrect and consistent use of condoms during sex can prevent trichomoniasis.\nScope of the problem\nTrichomonas vaginalis\nis the most common non-viral STI. There were an estimated 156 million new cases of\nT."}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-1", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 1, "text": "t and consistent use of condoms during sex can prevent trichomoniasis.\nScope of the problem\nTrichomonas vaginalis\nis the most common non-viral STI. There were an estimated 156 million new cases of\nT. vaginalis\ninfection among people aged 15–49 years old in 2020 globally in 2020 (73.7 million in females, 82.6 million in males).\nApproximately one third of new infections in this age group occur in the WHO African Region, followed by the Region of the Americas.\nTransmission\nSexually active people can get trichomoniasis by having sex without a condom with a partner who has trichomoniasis.\nSymptoms\nTrichomoniasis infection in women may be symptomatic or asymptomatic. Vaginal discharge is the main symptom that women may present, and can be accompanied by itch, pain when urinating and pain during intercourse. In men, most infections are asymptomatic but some experience penile discharge or pain when urinating.\nSymptomatic women can have vaginal discharge, which may appear purulent. Other symptoms include a red and sore vagina. The person with the infection can also feel pain during intercourse and urination. In women, when\nT."}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-2", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 2, "text": "n have vaginal discharge, which may appear purulent. Other symptoms include a red and sore vagina. The person with the infection can also feel pain during intercourse and urination. In women, when\nT. vaginalis\nis present, discharge can be observed in the vagina during a speculum examination by a health provider.\nMen are often asymptomatic, but some experience urethral discharge/urethritis, or penile irritation.\nPrevention\nTrichomoniasis is a preventable condition.\nThe most effective method to prevent sexual transmission of trichomoniasis and various other STIs is by consistently and correctly using condoms.\nPeople diagnosed with trichomoniasis should inform their sexual partners to prevent further transmission. If that is not possible, they should request support from the health provider to notify their sexual partners.\nDiagnosis\nHealthcare providers will discuss the patient’s medical and sexual history and conduct a genital examination, including speculum examination and palpation, to enable them to have important clues to clinical diagnosis. Diagnostic options include smear microscopy and antigen or molecular testing."}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-3", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 3, "text": "examination, including speculum examination and palpation, to enable them to have important clues to clinical diagnosis. Diagnostic options include smear microscopy and antigen or molecular testing. The latter include nucleic acid amplification tests (NAAT), considered in some settings as a gold standard for diagnosing\nT. vaginalis.\nThese\ncan be performed in the lab. Vaginal or endocervical specimens are the preferred specimen type for diagnostic testing.\nIn many primary healthcare settings where diagnostic capacity for detecting\nT. vaginalis\nis not available, a\nsyndromic approach for case management\nis recommended.\nIn the presence of\nT. vaginalis\n(or vaginal discharge), tests for other sexually transmitted infections (such as HIV and syphilis) are recommended, together with notification of sexual partner(s).\nTreatment\nTrichomoniasis is treatable and curable.\nIt is best treated with the antibiotics metronidazole or tinidazole. Although resistance is uncommon, treatment failure occurs in a small proportion of cases."}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-4", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 4, "text": "Trichomoniasis is treatable and curable.\nIt is best treated with the antibiotics metronidazole or tinidazole. Although resistance is uncommon, treatment failure occurs in a small proportion of cases. Several second-line regimens are available and should be initiated by the healthcare professionals.\nWomen who present with vaginal discharge, and who are managed based on the syndromic approach are treated for bacterial vaginosis (BV), candidiasis and trichomoniasis. Metronidazole is indicated for both BV and trichomonas, while topical or oral antifungals are indicated for candidiasis.\nRecommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (‎anogenital warts)‎\nPossible complications\nPerinatal outcomes\nUntreated\nT. vaginalis\nis linked to adverse birth outcomes, including low birth weight, preterm delivery and premature rupture of membranes. Although uncommon, perinatal transmission of\nT. vaginalis\ncan occur, leading to vaginal and respiratory infections in newborns.\nHIV transmission\nT."}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-5", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 5, "text": "reterm delivery and premature rupture of membranes. Although uncommon, perinatal transmission of\nT. vaginalis\ncan occur, leading to vaginal and respiratory infections in newborns.\nHIV transmission\nT. vaginalis\ninfections are linked to a 1.5 times increased risk of HIV acquisition.\nWHO response\nThe WHO\nGlobal health sector strategies on HIV, viral hepatitis and STIs 2022–2030\naims for a 50% reduction in new cases of trichomoniasis by 2030. WHO collaborates with countries and partners to enhance people-centred STI case management methods, promote suitable treatment recommendations, and implement effective testing and partner services strategies.\nWHO also supports the development of accessible and affordable high-quality diagnostics and treatment options, as well as advancements in vaccine development. Additionally, WHO focuses on improving country and global-level monitoring of new infections.\nAlthough antimicrobial resistance in\nT."}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-6", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 6, "text": "reatment options, as well as advancements in vaccine development. Additionally, WHO focuses on improving country and global-level monitoring of new infections.\nAlthough antimicrobial resistance in\nT. vaginalis\nis not widespread, WHO closely monitors patterns of potential antimicrobial resistance of this pathogen to inform treatment recommendations and national policies.\nIn 2024, WHO published\nRecommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (‎anogenital warts)\n‎ to provide evidence-informed clinical and practical recommendations on case management of\nTrichomonas vaginalis\n.\nRelated\nGlobal health sector strategies 2022–2030\nGuidelines for the management of symptomatic sexually transmitted infections\nNews\nWHO expands guidance on sexually transmitted infections and reviews country progress on policy implementation\n26 July 2025\nNew report flags major increase in sexually transmitted infections,\namidst challenges in HIV and hepatitis\n21 May 2024\nFact sheets\nChlamydia\n21 November 2025\nHIV and AIDS\n15 July 2025\nSyphilis\n29 May 2025\nBacterial vaginosis\n21 November 2025\nFeature stories\nFour cura"}
{"id": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis-7", "source": "who/www.who.int_news-room_fact-sheets_detail_trichomoniasis.txt", "chunk_index": 7, "text": "amidst challenges in HIV and hepatitis\n21 May 2024\nFact sheets\nChlamydia\n21 November 2025\nHIV and AIDS\n15 July 2025\nSyphilis\n29 May 2025\nBacterial vaginosis\n21 November 2025\nFeature stories\nFour curable sexually transmitted infections - all you need to know\n6 June 2019"}
